Read time: 3 minutes.

Throughout 2024 we published blogs sharing scientific meeting recaps, educational content, personal stories, treatment news, and so much more. Below are the most popular articles we published in 2024. 

Read time: 2 minutes.  

Brain metastases (also called brain mets) develop when cancer from somewhere else in the body spreads to the brain.  

Lung cancer screening and early detection were major topics of discussion at the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference in Barcelona from September 13-17. This fourth and final blog in our series of updates summarizes highlights from these discussions. 

You can read the other update blogs from these fall science meetings: 

Read time: 5 minutes.  

This is Part 3 in our series on how drugs get approved to treat lung cancer.  

Read time: 6 minutes. 

This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development. 

Read time: 3 minutes.

This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks.

Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do.

Read time: 3 minutes.  

One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment.  

Read time: 2 minutes.  

Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials.  

Read time: 2 minutes

Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. 

LUNGevity spoke to an expert to help sort out the facts from the fiction. 

On April 18, 2024, the US Food and Drug Administration (FDA) announced the approval of alectinib to treat patients after surgical removal of ALK-positive non-small cell lung cancer (NSCLC).

The approval is supported by data from the phase 3 ALINA trial, which showed that treating patients with alectinib reduced the risk of disease recurrence by 76% compared to treating them with chemotherapy.

Alectinib is approved for use in patients with completely resected stage IB to IIIA ALK-positive NSCLC whose tumors are at least 4 cm wide.